09 Feb
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
WATERTOWN, Mass. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
10 Jan
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicity WATERTOWN, Mass. and BOSTON , Jan.
05 Jan
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
WATERTOWN, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management